Serum potassium levels predict blood pressure response to aldosterone antagonists in resistant hypertension

Hypertension Research

Volumn 37, Issue 12, 2014, Pages 1037-1041

  Shlomai, Gadi ^a   Sella, Tal ^a   Sharabi, Yehonatan ^a   Leibowitz, Avshalom ^a   Grossman, Ehud ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; POTASSIUM; SPIRONOLACTONE; ANTIHYPERTENSIVE AGENT; MINERALOCORTICOID ANTAGONIST;

ADD ON THERAPY; AGED; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; BODY MASS; CLINICAL ARTICLE; DIASTOLIC BLOOD PRESSURE; DRUG RESPONSE; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; MALE; MICROALBUMINURIA; MORBIDITY; MORTALITY; OBESITY; POTASSIUM BLOOD LEVEL; RESISTANT HYPERTENSION; SENESCENCE; SYSTOLIC BLOOD PRESSURE; BLOOD; DRUG EFFECTS; DRUG RESISTANCE; HYPERTENSION; MIDDLE AGED; PREDICTIVE VALUE; PROGNOSIS; RETROSPECTIVE STUDY;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG RESISTANCE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; POTASSIUM; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SPIRONOLACTONE;

EID: 84907279078     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2014.77     Document Type: Article

References (25)

1. Lowe LP, Greenland P, Ruth KJ, Dyer AR, Stamler R, Stamler J. Impact of major cardiovascular disease risk factors, particularly in combination, on 22-year mortality in women and men. Arch Iintern Med 1998; 158: 2007-2014.
2. Krause T, Lovibond K, Caulfield M, McCormack T, Williams B. Management of hypertension: summary of nice guidance. BMJ 2011; 343: d4891.
3. Dickerson JE, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999; 353: 2008-2013.
4. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Roger VL, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010; 121: e46-e215.
5. Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H, Poulter NR. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49: 839-845.
6. de Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 2010; 55: 147-152.
7. Jansen PM, Verdonk K, Imholz BP, Jan Danser AH, van den Meiracker AH. Long-Term use of aldosterone-receptor antagonists in uncontrolled hypertension: a retrospective analysis. Int J Hypertens 2011; 2011: 368140.
8. Lane DA, Shah S, Beevers DG. Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens 2007; 25: 891-894.
9. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16: 925-930.
10. Ouzan J, Perault C, Lincoff AM, Carre E, Mertes M. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002; 15: 333-339.
11. Sharabi Y, Adler E, Shamis A, Nussinovitch N, Markovitz A, Grossman E. Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension. Am J Hypertens 2006; 19: 750-755.
12. Vaclavik J, Sedlak R, Jarkovsky J, Kocianova E, Taborsky M. Effect of spironolactone in patients with resistant arterial hypertension in relation to age and sex: insights from the aspirant trial. Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 2012.
13. Vaclavik J, Sedlak R, Plachy M, Navratil K, Plasek J, Jarkovsky J, Vaclavik T, Husar R, Kocianova E, Taborsky M. Addition of spironolactone in patients with resistant arterial hypertension (aspirant): a randomized, double-blind, placebo-controlled trial. Hypertension 2011; 57: 1069-1075.
14. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, Mc GTS. Guidelines for management of hypertension: report of the Fourth Working Party of The British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004; 18: 139-185.
15. Khosla N, Kalaitzidis R, Bakris GL. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol 2009; 30: 418-424.
16. Marrs JC. Spironolactone management of resistant hypertension. Ann Pharmacother 2010; 44: 1762-1769.
17. Mahmud A, Mahgoub M, Hall M, Feely J. Does aldosterone-To-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone? Am J Hypertens 2005; 18: 1631-1635.
18. Prisant LM, Krum H, Roniker B, Krause SL, Fakouhi K, He W. Can renin status predict the antihypertensive efficacy of eplerenone add-on therapy? J Clin Pharmacol 2003; 43: 1203-1210.
19. Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-Term angiotensin II suppression. J Endocrinol 1981; 91: 457-465.
20. Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, Veglio F. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002; 40: 897-902.
21. Rocha R, Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann NY Acad Sci 2002; 970: 89-100.
22. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48: 2293-2300.
23. Goodfriend TL, Ball DL, Egan BM, Campbell WB, Nithipatikom K. Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension 2004; 43: 358-363.
24. Lamounier-Zepter V, Ehrhart-Bornstein M. Fat tissue metabolism and adrenal steroid secretion. Curr Hyperten Rep 2006; 8: 30-34.
25. Pausova Z. From big fat cells to high blood pressure: a pathway to obesity-Associated hypertension. Curr Opin Nephrol Hypertens 2006; 15: 173-178.